BEDFORD, Mass. (AP) _ Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $24.2 million in its third quarter.

On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 31 cents.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.

The biotechnology company posted revenue of $12 million in the period, also falling short of Street forecasts. Four analysts surveyed by Zacks expected $14.7 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OCUL at https://www.zacks.com/ap/OCUL

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News